GSK pays Synta $15M in milestone fees for cancer drug

12/15/2008 | Boston Globe (tiered subscription model), The

Synta Pharmaceuticals got $15 million in milestone fees from GlaxoSmithKline in a collaboration to develop and market elesclomol, an experimental drug designed to destroy cancer cells. Under the deal, Synta is entitled to a total payment of $585 million for reaching clinical-testing goals or making regulatory submissions.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT